These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 32598783)
1. [Advantages of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout]. Panevin TS; Eliseev MS; Shestakova MV; Nasonov EL Ter Arkh; 2020 Jun; 92(5):110-118. PubMed ID: 32598783 [TBL] [Abstract][Full Text] [Related]
2. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369 [TBL] [Abstract][Full Text] [Related]
3. The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia. Wang S Pak J Pharm Sci; 2018 Jul; 31(4(Special)):1623-1627. PubMed ID: 30203749 [TBL] [Abstract][Full Text] [Related]
4. [Hyperuricemia, gout, pseudogout and concomitant diseases]. Schmidt BM; Wagner AD Dtsch Med Wochenschr; 2011 Dec; 136(48):2489-91. PubMed ID: 22109583 [No Abstract] [Full Text] [Related]
5. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol. Cutolo M; Cimmino MA; Perez-Ruiz F Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079 [TBL] [Abstract][Full Text] [Related]
6. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia. Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549 [TBL] [Abstract][Full Text] [Related]
7. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis. Liu CW; Chang WC; Lee CC; Shau WY; Hsu FS; Wang ML; Chen TC; Lo C; Hwang JJ Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626 [TBL] [Abstract][Full Text] [Related]
8. Comparison of efficacy and safety between febuxostat and allopurinol in early post-renal transplant recipients with new onset of hyperuricemia. Shen X; Li J; Fu Q; Liu L; Gao X; Chen X; Chen P; Wang C J Clin Pharm Ther; 2019 Apr; 44(2):318-326. PubMed ID: 30582178 [TBL] [Abstract][Full Text] [Related]
9. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094 [TBL] [Abstract][Full Text] [Related]
10. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. Ernst ME; Fravel MA Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996 [TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy. Gupta MK; Singh JA Drugs; 2019 Apr; 79(5):531-541. PubMed ID: 30868398 [TBL] [Abstract][Full Text] [Related]
12. Associations of hyperuricemia, gout, and UA-lowering therapy with the risk of fractures: A meta-analysis of observational studies. Zong Q; Hu Y; Zhang Q; Zhang X; Huang J; Wang T Joint Bone Spine; 2019 Jul; 86(4):419-427. PubMed ID: 30910706 [TBL] [Abstract][Full Text] [Related]
13. Febuxostat for prevention of gout attacks. Pohar S; Murphy G Issues Emerg Health Technol; 2006 Aug; (87):1-4. PubMed ID: 16958189 [TBL] [Abstract][Full Text] [Related]
14. Febuxostat--treatment for hyperuricemia and gout? Moreland LW N Engl J Med; 2005 Dec; 353(23):2505-7. PubMed ID: 16339099 [No Abstract] [Full Text] [Related]
15. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847 [TBL] [Abstract][Full Text] [Related]
16. A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. Faruque LI; Ehteshami-Afshar A; Wiebe N; Tjosvold L; Homik J; Tonelli M Semin Arthritis Rheum; 2013 Dec; 43(3):367-75. PubMed ID: 24326033 [TBL] [Abstract][Full Text] [Related]
17. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584 [TBL] [Abstract][Full Text] [Related]
18. Anakinra treatment in patients with gout and type 2 diabetes. Vitale A; Cantarini L; Rigante D; Bardelli M; Galeazzi M Clin Rheumatol; 2015 May; 34(5):981-4. PubMed ID: 24733251 [TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy. Ruggeri M; Basile M; Drago C; Rolli FR; Cicchetti A Pharmacoeconomics; 2018 May; 36(5):625-636. PubMed ID: 29557073 [TBL] [Abstract][Full Text] [Related]
20. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]